publication date: Oct. 3, 2014
“These are Life-Saving Drugs. I’m Not Going To Stop Treating Patients, Right?”
The loss of discounts and rebates hospitals received for administering Genentech’s Avastin, Herceptin and Rituxan will increase costs to patients, said Scott Soefje, director of pharmacy at University Medical Center Brackenridge in Austin.
Soefje, who is also president-elect of the Hematology/Oncology Pharmacy Association, spoke with Paul Goldberg, editor and publisher of The Cancer Letter.
Paul Goldberg: Genentech is talking about drug integrity issues here, and referring—by name and not by name—to the Turkish Avastin caper [See Story on page 1]. Is it relevant here?
Scott Soefje: Drug counterfeiting is something we are always concerned about. Congress has enacted a pedigree law, the Drug Supply Chain Security Act, that goes into effect in January, in which the manufacturers and the wholesalers would have to provide to the ultimate users the documentation that the supply chain was secure and that this drug is actually what it says it is.
PG: However, community practices were buying drugs through specialty distributors for years. And the Turkish Avastin case was a way to circumvent those channels. Do you know anybody in any hospital who was in any way involved in this? How does this connect? I’ve gone through every one of those cases, and I don’t see a single hospital pharmacy involved here.
SS: And it’s not. It’s … Continue reading 40-37 Conversation with The Cancer Letter
To access this members-only content, please log in.
Institutional subscribers, please log in with your IP
If you're not a subscriber why not join today?
To gain access to the members only content click here
You will be given immediate access to premium content on the site.Click here to join.